AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7494563
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m²) + Cyclophosphamide (750 mg/m²)
Trial: 3893039
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g acetylsalicylic acid (ASA) for two days
Trial: 31805012
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg NAC BID for 12 weeks then TID for 12 weeks
Trial: 31805012
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg NAC BID for 12 weeks then TID for 12 weeks
Trial: 31805012
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg NAC BID for 12 weeks then TID for 12 weeks
Trial: 30376082
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of IPV doses
Trial: 22633184
Drug: 2-titration group
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2-titration group
Trial: 22633184
Drug: Single-titration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-titration group
Trial: 18164168
Drug: Debiasing technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debiasing technique (participants listing advantages and disadvantages of each treatment)
Trial: 12118746
Drug: Heparin bonded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin bonded extracorporeal circuits (group H)
Trial: 10094133
Drug: Serotonin 2A
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin 2A receptor variant (102T/C) in schizophrenic patients
Trial: 10094133
Drug: Clozapine treatment
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment in schizophrenic patients
Trial: 2139241
Drug: McKenzie method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: McKenzie method of treatment
Trial: 2103969
Drug: Heparin-glucuronilglucosaminoglycane treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-glucuronilglucosaminoglycane treatment
Trial: 7408684
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg acebutolol (Prent)
Trial: 28697113
Drug: Paracervical block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracervical block with 18 mL 1% lidocaine and 2 mL sodium bicarbonate
Trial: 23463624
Drug: Capecitabine and
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine and oral cyclophosphamide (CCy)
Trial: 20813884
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 μg plus fluticasone propionate 500 μg, twice a day
Trial: 19481079
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EVL, propranolol (dose titrated to reduce heart rate to 55 bpm), and ISMN (40 mg/day)
Trial: 19481079
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EVL, propranolol, and ISMN
Trial: 19481079
Drug: Cirrhotic patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cirrhotic patients in combination group
Trial: 11916195
Drug: Ropivacaine gel
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine gel (200 mg)
Trial: 10414879
Drug: Interferon-alpha2a (9MU/d)
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha2a (9MU/d) + zidovudine (2x250 mg/d)
Trial: 10414879
Drug: Bleomycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin (15 mg every 2 weeks) + zidovudine (2x250 mg/d)
Trial: 6778187
Drug: Tocainide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocainide (750 mg i.v. during a 15-minute period followed by 800 mg orally and later 400 mg t.i.d.)
Trial: 25645168
Drug: Therapist-guided internet-delivered
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided internet-delivered cognitive behavior therapy (iCBT)
Trial: 24025143
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with ornithine aspartate plus naloxone
Trial: 24025143
Drug: Traditional medical
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional medical treatment
Trial: 21429443
Drug: diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 75 mg/1 ml
Trial: 21429443
Drug: diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 75 mg/3 ml
Trial: 11430960
Drug: Other tocolytic
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other tocolytic agents
Trial: 2514653
Drug: Cicletanine 150-200
RxNorm normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine 150-200 mg/day
Trial: 4393354
Drug: Propranolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (5 to 1,280 mg orally)
Trial: 4393354
Drug: Sotalol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (5 to 1,280 mg orally)
Trial: 4393354
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (no drug)
Trial: 14756610
Drug: Cognitive trauma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive trauma therapy for battered women with PTSD (CTT-BW)
Trial: 11177402
Drug: Zidovudine and
RxNorm normalized name: zidovudine and lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine and didanosine (dual therapy)
Trial: 11177402
Drug: Zidovudine, didanosine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine, didanosine, and lamivudine (triple therapy)
Trial: 9638980
Drug: Normal-risk group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-risk group receiving CHOP chemotherapy
Trial: 9638980
Drug: High-risk patients
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk patients treated with low-dose CHOP
Trial: 9638980
Drug: Normal-risk patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-risk patients during chemotherapy
Trial: 8091999
Drug: Depot antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot antipsychotic medication during the initial 1-year period
Trial: 31178096
Drug: Medication-free period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-free period
Trial: 2694767
Drug: Maintenance antipsychotic
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance antipsychotic medication
Trial: 2734719
Drug: Antacid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid treatment (Rocgel)
Trial: 23786821
Drug: Buttermilk (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buttermilk (45 g/d)
Trial: 23786821
Drug: Placebo (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (45 g/d)
Trial: 16001993
Drug: PLD 50
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 50 mg/m2 I.V. on day 1 and cyclophosphamide 100 mg/m2 orally on days 1‐14 every 28‐day cycle
Trial: 16001993
Drug: PLD 30
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 30 mg/m2 plus cyclophosphamide 600 mg/m2 I.V. on day 1 every 21 days
Trial: 16001993
Drug: PLD 35
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 35 mg/m2 plus cyclophosphamide 600 mg/m2 I.V. on day 1 every 21 days
Trial: 3050905
Drug: Flurbiprofen 50
RxNorm normalized name: flurbiprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 50 mg preoperatively
Trial: 25782644
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg escitalopram daily from preanesthesia to postoperative day 6
Trial: 25782644
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily from preanesthesia to postoperative day 6
Trial: 19531592
Drug: PPAR alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPAR alpha agonist (20 microg/d GW590735)
Trial: 19531592
Drug: PPAR delta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPAR delta agonist (10 mg/d GW501516)
Trial: 19531592
Drug: PPAR gamma
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPAR gamma agonist (rosiglitazone)
Trial: 17569044
Drug: Vinorelbine (VRL)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (VRL) 20 mg m(‐2) i.v. on day 1, Docetaxel (DCT) 60 mg m(‐2) on day 1, Oral VRL 60 mg m(‐2) on day 15 every 3 weeks
Trial: 17569044
Drug: Vinorelbine (VRL)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (VRL) 20 mg m(‐2) i.v. with Docetaxel (DCT) 60 mg m(‐2) on day 1, Oral VRL 60 mg m(‐2) on day 15 every 3 weeks
Trial: 11208496
Drug: Drug I
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug I (propafenone, sotalol, or disopyramide)
Trial: 11208496
Drug: Drug II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug II (second antiarrhythmic drug)
Trial: 11208496
Drug: Amiodarone (Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (Drug III)
Trial: 30369161
Drug: Ningmitai capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ningmitai capsules (4 capsules per time, 3 times per day)
Trial: 30369161
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antibiotics or sodium diclofenac suppository on demand)
Trial: 27898683
Drug: Injection drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection drug use, polysubstance use, environmental risk exposures (past incarceration, police involvement, selling sex, HIV stigma)
Trial: 22421008
Drug: 6-month therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-month therapy group
Trial: 22421008
Drug: 12-month therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-month therapy group
Trial: 20167686
Drug: Increased water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased water intake of 3 L per day
Trial: 19074351
Drug: Modafinil administration
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil administration
Trial: 17190281
Drug: Topical nitroderivatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroderivatives
Trial: 8626044
Drug: Glycine-extended gastrin-17
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine-extended gastrin-17 infusion at three consecutive dose rates
Trial: 8626044
Drug: Glycine-extended gastrin-17
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine-extended gastrin-17 infusion
Trial: 8626044
Drug: Glycine-extended gastrin-17
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine-extended gastrin-17 infusion during constant-rate infusion after a protein meal
Trial: 1575169
Drug: Quinapril, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril, 20 mg, administered in the evening (10 PM)
Trial: 1575169
Drug: Quinapril, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril, 20 mg, administered in the morning (8 AM)
Trial: 3918178
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 50 mg daily for 6 to 9 months
Trial: 20713790
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of methylprednisolone
Trial: 29872803
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g high MW (HMW) barley beta-glucan
Trial: 29872803
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g low MW (LMW) barley beta-glucan
Trial: 29872803
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g LMW barley beta-glucan
Trial: 25254489
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of N-acetylcysteine (NAC) and saline
Trial: 25254489
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (NAC and NaHCO3) and saline
Trial: 9798043
Drug: Penicillin therapy
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin therapy (intramuscular benzylpenicillin, 50,000 U/[kg.d] for 5 days and then oral penicillin, 50 mg/[kg.d] for 5 days)
Trial: 9798043
Drug: Erythromycin therapy
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin therapy (50 mg/[kg.d] orally for 10 days)
Trial: 10921031
Drug: ATRA treatment
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA treatment
Trial: 20496177
Drug: BAK-PLO (baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAK-PLO (baclofen 10 mg, amitriptyline HCL 40 mg, ketamine 20 mg in pluronic lecithin organogel)
Trial: 19807931
Drug: Vaginal subcutaneous
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal subcutaneous injection of rhFSH (Puregon 300)
Trial: 19807931
Drug: Abdominal subcutaneous
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal subcutaneous injection of rhFSH (Puregon 300)
Trial: 18378608
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg BID
Trial: 8465834
Drug: MRFIT hypertensive
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRFIT hypertensive patients with diuretic-based pharmacologic regimen
Trial: 8465834
Drug: Average on-treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Average on-treatment DBP < 95 mm Hg in MRFIT
Trial: 26220816
Drug: Personal digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal digital assistant (e.g., iPod Touch)
Trial: 23017329
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 mg/45 kg)
Trial: 12771298
Drug: Calcijex injected
RxNorm normalized name: Calcijex Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcijex injected directly into the PTG (2 microg/ml preparation)
Trial: 12771298
Drug: Calcijex injected
RxNorm normalized name: Calcijex Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcijex injected directly into the PTG (1 microg/ml preparation)
Trial: 8427339
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (20 g)
Trial: 3296854
Drug: Standard anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anesthetic and analgesic techniques without EAA
Trial: 30949742
Drug: B.T. Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B.T. Enema (sodium dihydrogen phosphate + disodium hydrogen phosphate) 135 ml
Trial: 27190094
Drug: DREAMS 2G
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DREAMS 2G drug-eluting absorbable metal scaffold
Trial: 19307994
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oregovomab infusion on the same day as chemotherapy (SIM)
Trial: 19307994
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oregovomab infusion 1 week after chemotherapy (OWD)
Trial: 19307994
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oregovomab infusion (both SIM and OWD)
Trial: 19307994
Drug: Front-line chemotherapy
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Front-line chemotherapy with carboplatin-paclitaxel
Trial: 19307994
Drug: Front-line chemotherapy
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Front-line chemotherapy with carboplatin-paclitaxel combined with oregovomab
Trial: 16391383
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of nitroprusside
Trial: 16391383
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of adenosine
Trial: 16391383
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of verapamil
Trial: 16391383
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of nitroglycerin (control group)
Trial: 10647318
Drug: Control programs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control programs (shorter outpatient programs or no treatment)
Trial: 9302302
Drug: Percutaneous drainage
RxNorm normalized name: PLEURX DRAINAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous drainage with albendazole (10 mg/kg/day for 8 weeks)
Trial: 8331011
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human erythropoietin (r‐HuEPO) at a dose of 200 units/kg/day, five times a week with iron supplements (Fe SO4, 325 mg. p.o., t.i.d.)
Trial: 3304952
Drug: Cyclandelate (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate (3.2 g daily in 2 doses)
Trial: 3304952
Drug: Cyclandelate with
RxNorm normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate with concomitant cholestyramine (16 g daily)
Trial: 3304952
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with concomitant cholestyramine (16 g daily)
Trial: 22889084
Drug: Platform-switching implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switching implants (58 implants restored with medialised abutments)
Trial: 22889084
Drug: Standard platform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard platform implants (56 implants restored with standard matching-diameter abutments)
Trial: 15752888
Drug: RT/CCT (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT/CCT (70 to 72.5 Gy accelerated hyperfractionated RT at 1.25 Gy b.i.d. with 2 cycles of CDDP (12‐20 mg/m(2)/d x 5 days) and continuous infusion 5‐FU (600 mg/m(2)/d x 5 days) during Week 1 and Week 6)
Trial: 11890430
Drug: Chiropractic technique,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic technique, lumbar spine flexion‐distraction, combined with manual Trigger Point Therapy
Trial: 7653696
Drug: Sertraline (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50-200 mg/day, flexible dosing)
Trial: 2672480
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with fluorouracil (5‐FU) (400 mg/m2 i.v., days 1‐5) and lomustine (CCNU) (100 mg/m2 per os on day 5) every 6 weeks for 9 cycles
Trial: 2672480
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (surgery alone)
Trial: 2672480
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with fluorouracil (5‐FU) and lomustine (CCNU)
Trial: 55646
Drug: Intrapleural B.C.G.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural B.C.G.
Trial: 55646
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no B.C.G. treatment)
Trial: 26957290
Drug: Paracetamol 325
RxNorm normalized name: Paracetamol 325 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 325 mg/tramadol 37.5 mg
Trial: 18330060
Drug: L-glutamine ORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine ORS
Trial: 15893170
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg folic acid
Trial: 10608624
Drug: PRP‐T (Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP‐T (Hib conjugate vaccine combined with DTP)
Trial: 1750637
Drug: Caudal blockade
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal blockade with bupivacaine 20 ml 0.5%